Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2016

01-05-2016 | Original Article

The role of patient-based treatment planning in peptide receptor radionuclide therapy

Authors: Deni Hardiansyah, Christian Maass, Ali Asgar Attarwala, Berthold Müller, Peter Kletting, Felix M. Mottaghy, Gerhard Glatting

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2016

Login to get access

Abstract

Background

Accurate treatment planning is recommended in peptide-receptor radionuclide therapy (PRRT) to minimize the toxicity to organs at risk while maximizing tumor cell sterilization. The aim of this study was to quantify the effect of different degrees of individualization on the prediction accuracy of individual therapeutic biodistributions in patients with neuroendocrine tumors (NETs).

Methods

A recently developed physiologically based pharmacokinetic (PBPK) model was fitted to the biokinetic data of 15 patients with NETs after pre-therapeutic injection of 111In-DTPAOC. Mathematical phantom patients (MPP) were defined using the assumed true (true MPP), mean (MPP 1A) and median (MPP 1B) parameter values of the patient group. Alterations of the degree of individualization were introduced to both mean and median patients by including patient-specific information as a priori knowledge: physical parameters and hematocrit (MPP 2A/2B). Successively, measurable individual biokinetic parameters were added: tumor volume V tu (MPP 3A/3B), glomerular filtration rate GFR (MPP 4A/4B), and tumor perfusion f tu (MPP 5A/5B). Furthermore, parameters of MPP 5A/5B and a simulated 68Ga-DOTATATE PET measurement 60 min p.i. were used together with the population values used as Bayesian parameters (MPP 6A/6B). Therapeutic biodistributions were simulated assuming an infusion of 90Y-DOTATATE (3.3 GBq) over 30 min to all MPPs. Time-integrated activity coefficients were predicted for all MPPs and compared to the true MPPs for each patient in tumor, kidneys, spleen, liver, remainder, and whole body to obtain the relative differences RD.

Results

The large RD values of MPP 1A [RDtumor = (625 ± 1266)%, RDkidneys = (11 ± 38)%], and MPP 1B [RDtumor = (197 ± 505)%, RDkidneys = (11 ± 39)%] demonstrate that individual treatment planning is needed due to large physiological differences between patients. Although addition of individual patient parameters reduced the deviations considerably [MPP 5A: RDtumor = (−2 ± 27)% and RDkidneys = (16 ± 43)%; MPP 5B: RDtumor = (2 ± 28)% and RDkidneys = (7 ± 40)%] errors were still large. For the kidneys, prediction accuracy was considerably improved by including the PET measurement [MPP 6A/MPP 6B: RDtumor = (−2 ± 22)% and RDkidneys = (−0.1 ± 0.5)%].

Conclusion

Individualized treatment planning is needed in the investigated patient group. The use of a PBPK model and the inclusion of patient specific data, e.g., weight, tumor volume, and glomerular filtration rate, do not suffice to predict the therapeutic biodistribution. Integrating all available a priori information in the PBPK model and using additionally PET data measured at one time point for tumor, kidneys, spleen, and liver could possibly be sufficient to perform an individualized treatment planning.
Appendix
Available only for authorised users
Literature
1.
de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. 90Yttrium and 111Indium labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997;24:368–71.PubMed
2.
Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10 Suppl 2:S23–9.CrossRefPubMed
3.
Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med. 1997;24:792–5.PubMed
4.
Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging. 2010;37:1018–31.CrossRefPubMed
5.
Cremonesi M, Botta F, Di Dia A, Ferrari M, Bodei L, De Cicco C, et al. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging. 2010;54:37–51.PubMed
6.
Cremonesi M, Ferrari M, Di Dia A, Botta F, De Cicco C, Bodei L, et al. Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy. Q J Nucl Med Mol Imaging. 2011;55:155–67.PubMed
7.
Glatting G, Bardiès M, Lassmann M. Treatment planning in molecular radiotherapy. Z Med Phys. 2013;23:262–9.CrossRefPubMed
8.
Kletting P, Bunjes D, Reske SN, Glatting G. Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model. J Nucl Med. 2009;50:296–302.CrossRefPubMed
9.
Thomas SR. Options for radionuclide therapy: from fixed activity to patient-specific treatment planning. Cancer Biother Radiopharm. 2002;17:71–82.CrossRefPubMed
10.
Marincek N, Jorg AC, Brunner P, Schindler C, Koller MT, Rochlitz C, et al. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med. 2013;11:17–27.CrossRefPubMedPubMedCentral
11.
Kletting P, Kull T, Bunjes D, Luster M, Reske SN, Glatting G. Optimal preloading in radioimmunotherapy with anti-CD45 antibody. Med Phys. 2011;38:2572–8.CrossRefPubMed
12.
Lassmann M, Chiesa C, Flux G, Bardies M, Committee ED. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38:192–200.CrossRefPubMed
13.
Strigari L, Konijnenberg M, Chiesa C, Bardies M, Du Y, Gleisner KS, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1976–88.CrossRefPubMed
14.
15.
Kletting P, Kull T, Bunjes D, Mahren B, Luster M, Reske SN, et al. Radioimmunotherapy with anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic model. J Nucl Med. 2010;51:484–91.CrossRefPubMed
16.
Kletting P, Müller B, Erentok B, Schmaljohann J, Behrendt FF, Reske SN, et al. Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. Med Phys. 2012;39:5708–17.CrossRefPubMed
17.
Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res. 2007;13:2768–76.CrossRefPubMed
18.
Heatherington AC, Vicini P, Golde H. A pharmacokinetic/pharmacodynamic comparison of SAAM II and PC/WinNonlin modeling software. J Pharm Sci. 1998;87:1255–63.CrossRefPubMed
19.
Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47:1467–75.PubMed
20.
Chalkia MT, Stefanoyiannis AP, Chatziioannou SN, Round WH, Efstathopoulos EP, Nikiforidis GC. Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review. Australas Phys Eng Sci Med. 2015;38:7–22.CrossRefPubMed
21.
Tsougos I, Loudos G, Georgoulias P, Theodorou K, Kappas C. Patient-specific internal radionuclide dosimetry. Nucl Med Commun. 2010;31:97–106.CrossRefPubMed
22.
Garkavij M, Nickel M, Sjogreen-Gleisner K, Ljungberg M, Ohlsson T, Wingardh K, et al. 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116:1084–92.CrossRefPubMed
23.
Glatting G, Landmann M, Kull T, Wunderlich A, Blumstein NM, Buck AK, et al. Internal radionuclide therapy: the ULMDOS software for treatment planning. Med Phys. 2005;32:2399–405.CrossRefPubMed
24.
Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484–92.CrossRefPubMed
25.
Snyder WS, Cook MJ, Nasset ES, Karhausen RS, Howells GP. Report of the task group on reference man. Ann ICRP. 1979;3:iii.
26.
Durkee BY, Mudd SR, Roen CN, Clipson L, Newton MA, Weichert JP, et al. Reproducibility of tumor volume measurement at microCT colonography in living mice. Acad Radiol. 2008;15:334–41.CrossRefPubMedPubMedCentral
27.
Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53:353–9.CrossRefPubMed
28.
Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, et al. Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. Gynecol Oncol. 2012;126:375–80.CrossRefPubMed
29.
Sugawara Y, Murase K, Kikuchi K, Sakayama K, Miyazaki T, Kajihara M, et al. Measurement of tumor blood flow using dynamic contrast-enhanced magnetic resonance imaging and deconvolution analysis: a preliminary study in musculoskeletal tumors. J Comput Assist Tomogr. 2006;30:983–90.CrossRefPubMed
30.
Edwards WB, Fields CG, Anderson CJ, Pajeau TS, Welch MJ, Fields GB. Generally applicable, convenient solid-phase synthesis and receptor affinities of octreotide analogs. J Med Chem. 1994;37:3749–57.CrossRefPubMed
31.
Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.CrossRefPubMed
32.
Svensson J, Berg G, Wangberg B, Larsson M, Forssell-Aronsson E, Bernhardt P. Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment. Eur J Nucl Med Mol Imaging. 2015;42:947–55.CrossRefPubMedPubMedCentral
33.
Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19.CrossRefPubMed
34.
Harris A, Kamishima T, Hao HY, Kato F, Omatsu T, Onodera Y, et al. Splenic volume measurements on computed tomography utilizing automatically contouring software and its relationship with age, gender, and anthropometric parameters. Eur J Radiol. 2010;75:e97–101.CrossRefPubMed
35.
Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 2005;11:1481–93.CrossRefPubMed
36.
Leggett RW, Williams LR. A proposed blood circulation model for reference man. Health Phys. 1995;69:187–201.CrossRefPubMed
37.
Thomas GD, Chappell MJ, Dykes PW, Ramsden DB, Godfrey KR, Ellis JR, et al. Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model. Cancer Res. 1989;49:3290–6.PubMed
38.
Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049–58.CrossRefPubMed
39.
Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:514–23.CrossRefPubMed
40.
Hänscheid H, Sweeney RA, Flentje M, Buck AK, Lohr M, Samnick S, et al. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. Eur J Nucl Med Mol Imaging. 2012;39:1284–8.CrossRefPubMed
41.
Lyra M, Lagopati N, Charalambatou P, Vamvakas I. Patient-specific dosimetry in radionuclide therapy. Radiat Prot Dosim. 2011;147:258–63.CrossRef
42.
Walrand S, Barone R, Pauwels S, Jamar F. Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts. Eur J Nucl Med Mol Imaging. 2011;38:1270–80.CrossRefPubMed
43.
Hindorf C, Glatting G, Chiesa C, Linden O, Flux G, Committee ED. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37:1238–50.CrossRefPubMed
44.
Oomen SP, Hofland LJ, van Hagen PM, Lamberts SW, Touw IP. Somatostatin receptors in the haematopoietic system. Eur J Endocrinol. 2000;143 Suppl 1:S9–14.CrossRefPubMed
45.
Peluso G, Mansi L. Immunity and somatostatin receptors. Minerva Endocrinol. 2001;26:111–7.PubMed
46.
Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138–46.CrossRefPubMedPubMedCentral
47.
Pereira JM, Stabin MG, Lima FR, Guimaraes MI, Forrester JW. Image quantification for radiation dose calculations—limitations and uncertainties. Health Phys. 2010;99:688–701.
Metadata
Title
The role of patient-based treatment planning in peptide receptor radionuclide therapy
Authors
Deni Hardiansyah
Christian Maass
Ali Asgar Attarwala
Berthold Müller
Peter Kletting
Felix M. Mottaghy
Gerhard Glatting
Publication date
01-05-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3248-6

Other articles of this Issue 5/2016

European Journal of Nuclear Medicine and Molecular Imaging 5/2016 Go to the issue

Original Article

In vivo biokinetic and metabolic characterization of the 68Ga-labelled α5β1-selective peptidomimetic FR366

Short Communication

Molecular imaging of cholinergic processes in prostate cancer using 11C-donepezil and 18F-FEOBV

Original Article

Impact of consensus contours from multiple PET segmentation methods on the accuracy of functional volume delineation

Book Review

L. Mansi, E. Lopci, V. Cuccurullo and A. Chiti (eds): Clinical Nuclear Medicine in Pediatrics

Editorial Commentary

Commentary on: “Occupational radiation exposure of medical staff performing 90Y-loaded microsphere radioembolization”

Original Article

Diagnostic value of combining 11C-choline and 18F-FDG PET/CT in hepatocellular carcinoma